HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery

Current Opinion in Drug Discovery and Development

Volumn 6, Issue 4, 2003, Pages 462-469

  Netzer, Rainer ^a   Bischoff, Ulrike ^a   Ebneth, Andreas ^a  

^a EVOTEC UK LTD   (United Kingdom)

Author keywords

Automated patch clamp; Fluorescence assay; Flux assay; HERG; HTS; Ion channel

Indexed keywords

ION CHANNEL; POTASSIUM CHANNEL; RUBIDIUM;

BINDING ASSAY; ELECTRIC POTENTIAL; ELECTROPHYSIOLOGY; FLUORESCENCE; HEART MUSCLE POTENTIAL; HIGH THROUGHPUT SCREENING; ION CURRENT; MEMBRANE POTENTIAL; QT INTERVAL; REVIEW; SCREENING;

ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FLUORESCENT DYES; HEART; HUMANS; ION CHANNELS; LONG QT SYNDROME; MYOCARDIUM; RUBIDIUM;

EID: 0041528452     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. De Ponti F, Poluzzi E, Montanaro N: QT-interval prolongation by noncardiac drugs: Lessons to be learned from recent experience. Eur J Clin Pharmacol (2000) 56(1):1-18. A review summarizing the effects of compounds on the QT interval, including a detailed list of drugs with QT-prolonging potential and possible mechanisms of action.
2. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: New estimates of drug development costs. J Health Econ (2003) 22(2):151-185.
3. Cavero I, Mestre M, Guillon JM, Crumb W: Drugs that prolong QT interval as an unwanted effect: Assessing their likelihood of inducing hazardous cardiac dysrhythmias. Exp Opin Pharmacother (2000) 1(5):947-973. A comprehensive review describing the effects of QT-prolonging compounds on cardiac action potentials and electrocardiograms, and summarizing the efforts of regulatory agencies to propose guidelines to increase the cardiac safety of compounds before they enter clinical trials.
4. FDA: ICH S7B: The Clinical Evaluation of QT Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Food and Drug Administation, Washington, DC, USA. http://www.fda.gov/ohrms/dockets/dockets/02n0518/ 02N-0518-TS00005-QT%20Prolongation/sld001.htm. An essential document for the approval of compounds, focusing on the necessity to test non-cardiovascular compounds for their QT prolongation potential.
5. MacKenzie I: Safety pharmacology for the non-clinical assessment of medicinal products. Drug Disc Today (2002) 7(4):232-234.
6. Marban E: Cardiac channelopathies. Nature (2002) 415(6868)213-218.
7. Bers DM: Cardiac excitation-contraction coupling. Nature (2002) 415(6868):198-205.
8. Keating MT, Sanguinetti MC: Molecular and cellular mechanisms of cardiac arrhythmias. Cell (2001) 104(4):569-580. An excellent review on the molecular, cellular and genetic mechanisms of arrhythmia.
9. + channels: Friend and foe. Trends Pharmacol Sci (2001) 22(5):240-246.
10. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell (1995) 80(5):795-803. The original report describing the location of HERG on the locus LQT2, linking HERG to cardiac arrhythmia and torsade de pointes.
11. Kr potassium channel. Cell (1995) 81(2):299-307.
12. Xu J, Wang X, Ensign B, Li M, Wu L, Guia A, Xu J: Ion-channel assay technologies: Quo vadis. Drug Disc Today (2001) 6(24):1278-1287.
13. 3H]Dofetilide binding to HERG transfected membranes: A potential high throughput preclinical screen. Eur J Pharmacol (2001) 430(1):147-148.
14. + channel? Eur J Pharmacol (2001) 412(3):203-212.
15. Wang J, Della Penna K, Wang H, Karczewski J, Connolly TM, Koblan KS, Bennett PB, Salata JJ: Functional and pharmacological properties of canine ERG potassium channels. Am J Physiol - Heart Circulat Physiol (2003) 284(1):H256-H267.
16. Hille B (Ed): Ionic Channels and Excitable Membranes. Sinauer Associates Inc, Sunderland, MA, USA (1992).
17. Tang W, Kang J, Wu X, Rampe D, Wang L, Shen H, Li Z, Dunnington D, Garyantes T: Development and evaluation of high throughput functional assay methods for HERG potassium channel. J Biomol Screen (2001) 6(5):325-331.
18. Cheng CS, Alderman D, Kwash J, Dessaint J, Patel R, Lescoe MK, Kinrade MB, Yu W: A high-throughput HERG potassium channel function assay: An old assay with a new look. Drug Dev Ind Pharm (2002) 28(2):177-191.
19. 86Rb efflux in rat blood vessels. Br J Pharmacol (1986) 88(1):121-128.
20. Terstappen GC: Functional analysis of native and recombinant ion channels using a high-capacity nonradioactive rubidium efflux assay. Anal Biochem 272(2):149-155.
21. Plasek J, Sigler K: Slow fluorescent indicators of membrane potential: A survey of different approaches to probe response analysis. J Photochem Photobiol B Biol (1996) 33(2):101-124.
22. 4(3)) in model systems and cells. Chem Phys Lipids (1994) 69(2):137-150.
23. Baxter DF, Kirk M, Garcia AF, Raimondi A, Holmqvist MH, Flint KK, Bojanic D, Distefano PS, Curtis R, Xie Y: A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels. J Biomol Screen (2002) 7(1):79-85.
24. Whiteaker KL, Gopalakrishnan SM, Groebe D, Shieh CC, Warrior U, Burns DJ, Coghlan MJ, Scott VE, Gopalakrishnan M: Validation of FLIPR membrane potential dye for high throughput screening of potassium channel modulators. J Biomol Screen (2001) 6(5):305-312.
25. Fitch RW, Xiao Y, Kellar KJ, Daly JW: Membrane potential fluorescence: A rapid and highly sensitive assay for nicotinic receptor channel function. Proc Natl Acad Sci USA (2003) 100(8):4909-4914.
26. Gonzalez JE, Tsien RY: Voltage sensing by fluorescence resonance energy transfer in single cells. Biophys J (1995) 69(4):1272-1280. The first paper describing the FRET technique, used for the detection of alteration of the membrane potential upon blockage of an ion channel.
27. Gonzalez JE, Tsien RY: Improved indicators of cell membrane potential that use fluorescence resonance energy transfer. Chem Biol (1997) 4(4):269-277.
28. Gonzalez JE, Maher MP: Cellular fluorescent indicators and voltage/ion probe reader (VIPR™): Tools for ion channel and receptor drug discovery. Recept Channels (2002) 8(5-6):283-295.
29. Falconer M, Smith F, Surah-Narwal S, Congrave G, Liu Z, Hayter P, Ciaramelia G, Keighley W, Haddock P, Waldron G, Sewing A: High-throughput screening for ion channel modulators. J Biomol Screen (2002) 7(5):460-465.
30. Zlokarnik G: Fluorescence assay for HERG inhibition and HT compound profiling for safety. IBC USA Conferences, Ion Channel Drug Targets, San Diego, CA, USA (2002).
31. Netzer R, Ebneth A, Bischoff U, Pongs O: Screening lead compounds for QT interval prolongation. Drug Disc Today (2001) 6(2):78-84.
32. Netzer R: Early screening of lead compounds for QT-prolongation. Global Outsourcing Rev (2003) 5(1):47-50.
33. Netzer R, Ebneth A, Bothmann H, Dorn A, Trube G: Fluorescence assay for screening neuroactive compounds on potential Interaction with HERG potassium channels. 32nd Society for Neuroscience Annual Meeting, Orlando, FL, USA (2002):Abs 546.1.
34. Mathes C: High quality recordings are critical when screening with an automated patch clamp system. IBC USA Conferences, Ion Channel Drug Targets, San Diego, CA, USA (2002).
35. Kiss L, Bennett PB, Uebele VN, Koblan KS, Kane SA, Neagle B, Schroder K: High throughput ion-channel pharmacology: Planar-array-based voltage clamp. ASSAY Drug Dev Technol (2003) 1(1-2):127-135.
36. Schroeder K, Neagle B, Trezise DJ, Worley J: IonWorks™ HT: A new high-throughput electrophysiology measurement platform. J Biomol Screen (2003) 8(1):50-64.
37. Lepple-Wienhus A, Ferlinz K, Seeger A, Schäfer A: Flip the tip: An automated, high quality, cost effective patch clamp screen. Recept Channels (2003) 9(1):13-17.
38. Fertig N, Blick RH, Behrends JC: Whole cell patch clamp recording performed on a planar glass chip. Biophys J (2002) 82(6):3056-3062.
39. Webster R, Leishman D, Walker D: Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discovery Dev (2002) 5(1):116-126. Comparison of the concentration/response relationship of drugs on HERG with free plasma concentrations.